Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Tax Provisions (2020 - 2025)

Maravai Lifesciences Holdings has reported Tax Provisions over the past 6 years, most recently at $6000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $6000.0 for Q4 2025, up 185.71% from a year ago — trailing twelve months through Dec 2025 was -$4.2 million (down 126.45% YoY), and the annual figure for FY2025 was -$4.2 million, down 126.45%.
  • Tax Provisions for Q4 2025 was $6000.0 at Maravai Lifesciences Holdings, up from -$92000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for MRVI hit a ceiling of $766.2 million in Q4 2023 and a floor of -$5.5 million in Q3 2023.
  • Median Tax Provisions over the past 5 years was $291000.0 (2024), compared with a mean of $43.6 million.
  • Peak annual rise in Tax Provisions hit 8970.3% in 2023, while the deepest fall reached 138.7% in 2023.
  • Maravai Lifesciences Holdings' Tax Provisions stood at $17.6 million in 2021, then plummeted by 51.95% to $8.4 million in 2022, then surged by 8970.3% to $766.2 million in 2023, then tumbled by 100.0% to -$7000.0 in 2024, then skyrocketed by 185.71% to $6000.0 in 2025.
  • The last three reported values for Tax Provisions were $6000.0 (Q4 2025), -$92000.0 (Q3 2025), and -$4.3 million (Q2 2025) per Business Quant data.